logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Treatment demand indicator (TDI)

Statistics found here the category is Demand for treatment for drug use (TDI)

Category Title
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2002 to 2007 Part (i) Percentage distribution by primary drug
TDI TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2002 to 2007 Part (ii) Numbers of clients by primary drug
TDI TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2007 in 25 EU Member States Part (i) New clients
TDI TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2007 in 25 EU Member States Part (ii) All clients
TDI TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2002 to 2007 Part (i) Percentage distribution by primary drug
TDI TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2002 to 2007 Part (ii) Numbers of clients by primary drug
TDI TDI-7. New outpatient clients injecting opioid as primary drug from 2003 to 2007 in 13 countries supplying data
TDI TDI-0. Data sources for clients entering treatment
TDI TDI-1. Clients entering treatment and reporting treatment units by country, 2007 or most recent year available
TDI TDI-2. Clients entering treatment and reporting treatment units, 1997 to 2007 Part (i) New clients by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1997 to 2007 Part (ii) All clients by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1997 to 2007 Part (iii) Reporting treatment units by country and year of treatment
TDI TDI-2. Clients entering treatment and reporting treatment units, 1997 to 2007 Part (iv) Types of reporting treatment unit by country
TDI TDI-3. New clients entering treatment by primary drug, 1997 to 2007 Part (i) New heroin clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1997 to 2007 Part (ii) New cocaine clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1997 to 2007 Part (iii) New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)
TDI TDI-3. New clients entering treatment by primary drug, 1997 to 2007 Part (iv) New cannabis clients by country and year of treatment (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2007 or most recent year available Part (i) New clients by country and gender (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2007 or most recent year available Part (ii) All clients by country and gender (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2007 or most recent year available Part (iii) New clients by country and age (%)
TDI TDI-4. Demographic characteristics of clients entering treatment, 2007 or most recent year available Part (iv) All clients by country and age (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2007 or most recent year available Part (i) New clients by country and primary drug (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2007 or most recent year available Part (ii) All clients by country and primary drug (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2007 or most recent year available Part (iii) New clients by country and rates of injection of primary drug (%)
TDI TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2007 or most recent year available Part (iv) All clients by country and rates of injection of primary drug (%)
TDI TDI-6. Incidence of treatment demand for drug use, 2007 or most recent year available — new clients by country (rate per 100 000 population)
TDI TDI-7. Data coverage, 2007 or most recent year available Part (i) Clients entering treatment by country and type of treatment centre and type of client
TDI TDI-7. Data coverage, 2007 or most recent year available Part (ii) Units by country and type of treatment centre and reporting status
TDI TDI-8. Primary use of stimulants of clients entering treatment, 2007 or most recent year available Part (i) New clients by country and type of stimulant (%)
TDI TDI-8. Primary use of stimulants of clients entering treatment, 2007 or most recent year available Part (ii) All clients by country and type of stimulant (%)
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2007 or most recent year available Part (i) New outpatient clients by country and gender
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2007 or most recent year available Part (ii) All outpatient clients by country and by gender
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2007 or most recent year available Part (iii) New outpatient clients by country and age
TDI TDI-9. Demographic characteristics of clients entering outpatient treatment, 2007 or most recent year available Part (iv) All outpatient clients by country and age
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (iii) All outpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (v) New inpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (vii) All inpatient clients, age distribution by primary drug (%)
TDI TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2007 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (iii) All outpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (v) New inpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age at first use (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (vii) All inpatient clients, age at first use distribution by primary drug (%)
TDI TDI-11. Age at first use of primary drug among clients according to primary drug for which they enter treatment — EU summary of clients entering treatment, 2007 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age at first use (%)
TDI TDI-12. Education status of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2007 or most recent year available Part (ii) All outpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2007 or most recent year available Part (iii) New inpatient clients by country and education status (%)
TDI TDI-12. Education status of clients entering treatment, 2007 or most recent year available Part (iv) All inpatient clients by country and education status (%)
TDI TDI-13. Labour status of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2007 or most recent year available Part (ii) All outpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2007 or most recent year available Part (iii) New inpatient clients by country and labour status (%)
TDI TDI-13. Labour status of clients entering treatment, 2007 or most recent year available Part (iv) All inpatient clients by country and labour status (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2007 or most recent year available Part (i) New outpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2007 or most recent year available Part (ii) All outpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2007 or most recent year available Part (iii) New inpatient clients by country and with whom living (%)
TDI TDI-14. Persons with whom client is living on entering treatment, 2007 or most recent year available Part (iv) All inpatient clients by country and with whom living (%)
TDI TDI-15. Percentage distribution of living conditions for clients entering treatment in 2007 Part (i) New clients entering outpatient treatment
TDI TDI-15. Percentage distribution of living conditions for clients entering treatment in 2007 Part (ii) All clients entering outpatient treatment
TDI TDI-15. Percentage distribution of living conditions for clients entering treatment in 2007 Part (iii) New clients entering inpatient treatment
TDI TDI-15. Percentage distribution of living conditions for clients entering treatment in 2007 Part (iv) All clients entering inpatient treatment
TDI TDI-16. Source of referral of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2007 or most recent year available Part (ii) All outpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2007 or most recent year available Part (iii) New inpatient clients by country and source of referral (%)
TDI TDI-16. Source of referral of clients entering treatment, 2007 or most recent year available Part (iv) All inpatient clients by country and source of referral (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (i) New opioid outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (ii) All opioid outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (iii) New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (iv) All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (vii) New hypnotics and sedatives outpatient clients by country and usual route of administration (%)
TDI TDI-17. Route of administration by primary drug of clients entering treatment, 2007 or most recent year available Part (viii) All hypnotics and sedatives outpatient clients by country and usual route of administration
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2007 or most recent year available Part (ii) All outpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2007 or most recent year available Part (iii) New inpatient clients by primary drug and frequency of use (%)
TDI TDI-18. Frequency of use of primary drug of clients entering treatment, 2007 or most recent year available Part (iv) All inpatient clients by primary drug and frequency of use (%)
TDI TDI-19. Primary drug of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2007 or most recent year available Part (ii) All outpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2007 or most recent year available Part (iii) New inpatient clients by country and primary drug (%)
TDI TDI-19. Primary drug of clients entering treatment, 2007 or most recent year available Part (iv) All inpatient clients by country and primary drug (%)
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2007 or most recent year available Part (i) New outpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2007 or most recent year available Part (ii) All outpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2007 or most recent year available Part (iii) New inpatient clients, ratio of males to females by country and primary drug
TDI TDI-21. Gender ratio by primary drug of clients entering treatment, 2007 or most recent year available Part (iv) All inpatient clients, ratio of males to females by country and primary drug
TDI TDI-22. Secondary drugs cited by clients entering treatment, 2007 or most recent year available Part (i) Outpatient units
TDI TDI-22. Secondary drugs cited by clients entering treatment, 2007 or most recent year available Part (ii) Inpatient units
TDI TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2007 or most recent year available Part (i) New clients by country and primary drug and type of treatment centre (%)
TDI TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2007 or most recent year available Part (ii) All clients by country and primary drug and type of treatment centre (%)
TDI TDI-25. Percentage distribution of age by gender among all clients entering outpatient treatment with primary drug: opioids, cocaine, stimulants and cannabis in 2007 for countries supplying data
TDI TDI-32. Mean age by gender by primary drug among all clients entering outpatient and inpatient treatment in 2007 Part (i) Outpatient clients
TDI TDI-32. Mean age by gender by primary drug among all clients entering outpatient and inpatient treatment in 2007 Part (ii) Inpatient clients
TDI TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering outpatient and inpatient treatment in 2007 Part (i) Outpatient treatment centres
TDI TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering outpatient and inpatient treatment in 2007 Part (ii) Inpatient treatment centres
TDI TDI-36. Primary amphetamine use among new clients entering treatment (%), 2002 to 2007
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2007 or most recent year available Part (i) All clients by country and primary drug and type of treatment unit
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2007 or most recent year available Part (ii) Outpatient clients by primary drug and mean age and gender ratio
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2007 or most recent year available Part (iii) Inpatient clients by primary drug and mean age and gender ratio
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2007 or most recent year available Part (iv) Outpatient clients by secondary drug and primary drug
TDI TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2007 or most recent year available Part (v) Inpatient clients by secondary drug and primary drug
TDI TDI-38. Primary opioid users and the proportion of opioid injectors among drug clients in 2007 or most recent year available in all types of treatment centres in 14 countries Part (i) Number of primary opioids clients
TDI TDI-38. Primary opioid users and the proportion of opioid injectors among drug clients in 2007 or most recent year available in all types of treatment centres in 14 countries Part (ii) % of primary opioids clients
TDI TDI-38. Primary opioid users and the proportion of opioid injectors among drug clients in 2007 or most recent year available in all types of treatment centres in 14 countries Part (iii) % of opioids injectors
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (i) New opioid outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (vii) New cannabis outpatient clients by country and age
TDI TDI-102. New clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (i) All opioid outpatient clients by country and ag
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (vii) All cannabis outpatient clients by country and age
TDI TDI-103. All clients entering outpatient treatment by primary drug and age, 2007 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (i) New opioid inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (iv) New hallucinogen inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (vii) New cannabis inpatient clients by country and age
TDI TDI-104. New clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and by age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (i) All opioid inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (vii) All cannabis inpatient clients by country and age
TDI TDI-105. All clients entering inpatient treatment by primary drug and age, 2007 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (i) New opioid outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vii) New cannabis outpatient clients by country and age at first use
TDI TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (i) All opioid outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vii) All cannabis outpatient clients by country and age at first use
TDI TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (i) New opioid inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iv) Number of clients using hallucinogens as primary drug
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vii) New cannabis inpatient clients by country and age at first use
TDI TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (i) All opioid inpatient clients by country and age at first
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (vii) All cannabis inpatient clients by country and age at first use
TDI TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2007 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age at first use
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (i) New opioid outpatient clients by country and frequency of use (%
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (ii) All opioid outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (iii) New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (viii) All cannabis outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (iv) All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2007 or most recent year available Part (vii) Percentage distribution amongst new clients with cannabis as primary drug
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (i) New opioid inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (ii) All opioid inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (iii) New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (iv) All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (v) New stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (vi) All stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (vii) Percentage distribution amongst new clients with cannabis as primary drug
TDI TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2007 or most recent year available Part (viii) All cannabis inpatient clients by country and frequency of use (%)
TDI TDI-113. All clients entering treatment for opioids by country and type of opioid misused (%), 2007 or most recent year available
TDI TDI-114. Primary opioids distribution among all clients entering treatment by country and type of treatment centre (%), 2007
TDI TDI-115. HCL and crack use of clients entering outpatient treatment, 2007 or most recent year available Part (i) New outpatient clients by country and type of cocaine product
TDI TDI-115. HCL and crack use of clients entering outpatient treatment, 2007 or most recent year available Part (ii) All outpatient clients by country and type of cocaine product

Page last updated: Monday, 16 November 2009